Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of 1 of the following:
• * Recurrent ovarian, fallopian tube, or peritoneal cavity cancer
• * Metastatic breast cancer
• * Advanced endometrial cancer
• Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m\^2
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Sex
• Not specified
• Menopausal status:
• Not specified
• Performance status
• Karnofsky 60-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• Hepatic
• AST and ALT ≤ 2 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2 times ULN
• Bilirubin normal
• Renal
• Creatinine ≤ 2.0 mg/dL
• Cardiovascular
• Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram
• No history of cardiac disease
• No New York Heart Association class II-IV heart disease
• No clinical evidence of congestive heart failure
• Other
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 3 months after completion of study treatment
• No active infection requiring antibiotics
• No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components
• No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 3 weeks since prior biologic or immunologic agents for this cancer
• Chemotherapy
• Recovered from prior chemotherapy
• * Alopecia or neuropathy allowed
• No prior doxorubicin HCl liposome
• Other concurrent chemotherapy allowed provided palmar-plantar erythrodysesthesia is not one of the side effects of the therapy
• * No concurrent cytarabine, fluorouracil, liposomal daunorubicin, or capecitabine
• * No concurrent pre-medication with corticosteroids as part of the chemotherapy regimen
• Endocrine therapy
• See Chemotherapy
• At least 3 weeks since prior and no concurrent oral or topical corticosteroids
• At least 1 week since prior hormonal therapy for this cancer
• * Concurrent hormone replacement therapy allowed
• Radiotherapy
• At least 3 weeks since prior radiotherapy for this cancer and recovered
• Surgery
• Recovered from prior surgery
• Other
• At least 3 weeks since prior and no other concurrent forms of pyridoxine except what is included in a multivitamin
• No prior anticancer treatment that contraindicates study treatment
• No concurrent amifostine or other protective agents